3085 results for "Psilocybin"
Novel Neurobiological Approaches to Anxiety-Related Disorders: Clinical and Neuroimaging Investigations of Psilocybin and Ketamine-Based Interventions
University of Southern Denmark Research Portal (University of Southern Denmark) – September 09, 2025
Summary
Psilocybin and ketamine show promise as psychological interventions for anxiety disorders, often resistant to conventional medicine. Neuroimaging reveals these psychedelics rapidly modulate neural networks. Investigations included one individual with GAD receiving ketamine-assisted psychotherapy and another with OCD microdosing psilocybin. A large-scale trial design for psilocybin microdosing in social anxiety is also presented. This emerging field of Psychedelics and Drug Studies informs psychotherapist training, vital for over 600,000 Francophone patients seeking mental health support.
Abstract
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD)...
Should addiction researchers be interested in psychedelic science?
Drug and Alcohol Review – April 10, 2017
Summary
Psychedelics are revolutionizing addiction psychology. In an open-label drug study, 80% of 15 people treated with psilocybin for tobacco addiction remained abstinent at six months, far exceeding standard pharmacotherapies. A survey of 358 individuals reported 74% abstained for over two years. MDMA, a unique synthetic compound, also shows promise for trauma, with 86% of PTSD patients in an RCT no longer meeting criteria. These findings highlight significant neurotransmitter receptor influence on behavior, offering new hope for complex addiction and psychological conditions.
Abstract
As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychede...
Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.
Journal of affective disorders – June 09, 2025
Summary
A single dose of psilocybin, the active compound in psychedelic mushrooms, showed promising results for Veterans battling severe treatment-resistant depression. In this groundbreaking research, 80% of Veterans experienced significant relief at 6 months post-treatment, with half achieving complete remission. While benefits gradually decreased, 40% maintained improvement at one year, offering hope for those who haven't responded to conventional treatments.
Abstract
One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long...
The Emergence of Psilocybin in Psychiatry and Neuroscience
Pharmaceuticals – April 09, 2025
Summary
Psilocybin, a potent hallucinogen, is showing compelling promise in Psychiatry and Medicine. Emerging evidence from clinical trials supports its efficacy for conditions like Major depressive disorder and anxiety. This psychedelic compound, whose therapeutic action involves Neurotransmitter Receptor Influence on Behavior, offers new avenues in Psychology. Advances in Chemical synthesis and alkaloids are vital for broader access. As Psychedelics and Drug Studies progress, careful integration is key to realizing psilocybin's potential.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neur...
Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications
Pharmaceuticals – March 07, 2025
Summary
Producing pharmaceutical-grade psilocybin, a promising psychedelic alkaloid, is challenging despite its therapeutic potential. A review of 25 studies, selected from 9152 publications, illuminates optimal extraction chemistry from Psilocybe mushrooms. Ultrasonic bath extraction proved most efficient, with polar solvents and precise temperature crucial for yield. High-performance liquid chromatography (HPLC) was the primary method for quantifying these compounds. This biochemical engineering insight standardizes protocols for quality psilocybin, advancing drug studies beyond chemical synthesis, ensuring purer alkaloids for pharmacology.
Abstract
The growing body of evidence supporting the therapeutic efficacy of psychoactive substances, like psilocybin, has driven significant interest in re...
A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy
Journal of Psychoactive Drugs – January 07, 2025
Summary
A single patient's adverse psilocybin experience, a powerful hallucinogen, without a guiding psychotherapist resulted in inpatient psychiatry admission. This case, pivotal for Psychology and Psychedelics and Drug Studies, emphasizes the necessity of controlled settings. It highlights how experiential learning for prescribers, encompassing knowledge of chemical synthesis and alkaloids, is crucial. Such findings contribute to diverse academic research themes debating whether therapeutic support should be mandatory, especially as psilocybin nears FDA approval.
Abstract
As psilocybin awaits approval by the Food and Drug Administration (FDA), scholars debate whether psychedelic-assisted psychotherapy should be requi...
Psilocybin reduces functional correlation and the encoding of spatial information by neurons in mouse retrosplenial cortex
European Journal of Neuroscience – October 04, 2024
Summary
Psilocybin, a classic hallucinogen, profoundly disrupts spatial perception by altering activity in the retrosplenial cortex. Neuroscience reveals this psychedelic reduces the ability of neurons in this key cortex anatomy to specifically signal location and decreases the stability of their activity. This finding, crucial for Psychology and Psychedelics and Drug Studies, suggests a mechanism for disorientation. Biochemical analysis showed these effects are mediated by neurotransmitter receptor influence on behavior, specifically the serotonin 2A receptor. This increased neural "entropy" offers insight into how psilocybin impacts our sense of place.
Abstract
Abstract Psychedelic drugs have profound effects on perception, cognition and mood. How psychedelics affect neural signaling to produce these effec...
Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Both metformin and psilocybin show promising potential in protecting brain cells from Parkinson's disease damage. While metformin works by reducing cellular stress and preventing protein buildup, psilocybin promotes brain repair through serotonin pathway activation. This groundbreaking comparison reveals both compounds could offer prophylactic treatment options for neurodegenerative disease prevention.
Abstract
Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic...
Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.
Journal of affective disorders – January 15, 2025
Summary
A single dose of psilocybin showed remarkable results in Veterans battling severe depression that hadn't responded to multiple treatments. In this groundbreaking exploration, 60% of participating Veterans experienced significant relief from depression within three weeks, with over half achieving complete remission. The treatment proved effective even for those with PTSD, offering new hope for Veterans struggling with treatment-resistant depression.
Abstract
The enduring and severe depression often suffered by Veterans causes immense suffering and is associated with high rates of suicide and disability....
[Psilocybin fungi microdose treatment in major depressive disorder: a case report].
Vertex (Buenos Aires, Argentina) – July 10, 2024
Summary
A 19-year-old with severe major depressive disorder achieved complete symptom remission through carefully monitored psilocybin microdosing. Over 7 months, the patient safely discontinued conventional antidepressants while following a controlled psychedelic protocol. Benefits included enhanced social interaction, improved communication, and increased well-being.
Abstract
Major depression disorder is an entity with high prevalence and worldwide impact. Current treatments present a non-response rate of 15-30%, and cer...
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
Cancers – April 27, 2024
Summary
Psilocybin shows promise in psychiatry for cancer-related depression, but its path to becoming accessible medicine faces hurdles. Oregon's Measure 109, enacted in 2020, legalized psilocybin therapy, yet implementation is complex. This review synthesizes empirical data from various psychedelics and drug studies, highlighting challenges like ethical protocols, integration into healthcare, and ensuring equitable statewide access. Establishing rigorous care models requires addressing regulatory and logistical obstacles, moving beyond mere legalization.
Abstract
Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, s...
Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography - tandem mass spectrometry.
Analytica chimica acta – February 01, 2024
Summary
Magic mushrooms vary significantly in their psychedelic potency, with some strains containing nearly twice the active compounds as others. Scientists analyzed five popular strains using precise extraction methods to measure tryptamine compounds psilocybin and psilocin. The Creeper strain proved most potent at 1.36%, while Thai Cubensis contained 0.88% of these indoleamine compounds.
Abstract
A method for clinical potency determination of psilocybin and psilocin in hallucinogenic mushroom species Psilocybe cubensis was developed using li...
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Journal of psychiatric practice – September 01, 2023
Summary
Psilocybin, the active compound in "magic mushrooms," shows remarkable potential in treating mental health conditions like depression and anxiety. Research reveals that this naturally-occurring psychedelic works by altering brain connectivity and serotonin signaling, leading to profound shifts in perception and emotional processing. Clinical trials demonstrate significant improvements in treatment-resistant depression and cancer-related anxiety, with effects lasting months after a single dose.
Abstract
There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within t...
Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia
Journal of Addictive Diseases – August 04, 2023
Summary
The emerging trend of vaping the Hallucinogen Psilocybin presents significant concerns for Medicine and Psychiatry. Its growing use, particularly among individuals consuming Amphetamine-Type Stimulants and across broader Demography, highlights a critical gap in understanding. Forensic Toxicology and Drug Analysis reveal this rise. Unlike some insights from Cannabis and Cannabinoid Research, knowledge regarding Psilocybin's long-term health effects remains severely limited. Understanding the potential risks of this Psychedelic, especially for the younger population, is crucial for future Drug Studies.
Abstract
Psilocybin in vaping is growing among ATS users and across all populations. Unfortunately, knowledge regarding the long-term effects on health is l...
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study.
International medical case reports journal – January 01, 2023
Summary
A patient suffering from treatment-resistant neuropsychiatric Lyme disease found remarkable relief through carefully measured microdoses of psilocybin. When traditional antibiotics failed, this psychedelic compound reduced neuroinflammation and mental illness symptoms linked to the autoimmune response. The treatment improved cognitive function and mood without hallucinogenic effects, suggesting a promising new approach for Lyme-related encephalopathy.
Abstract
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease i...
Body mass index (BMI) does not predict responses to psilocybin
Journal of Psychopharmacology – November 14, 2022
Summary
A significant finding in clinical psychology reveals that a person's Body Mass Index (BMI) does not predict the intensity of their psilocybin experience or subsequent psychological well-being improvements. This is crucial for medicine and internal medicine, as it supports standardized dosing. Data from three studies, using a fixed 25 mg dose of this naturally occurring alkaloid, show that BMI doesn't influence overall altered states or emotional breakthroughs. While psilocybin influences behavior via neurotransmitter receptors, this research suggests that for psychedelic-assisted therapy, a fixed dose is effective across varying BMIs, simplifying drug studies and treatment context.
Abstract
Background: Psilocybin is a serotonin type 2A (5-HT 2A ) receptor agonist and naturally occurring psychedelic. 5-HT 2A receptor density is known to...
Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression
OpenAlex – March 10, 2025
Summary
Psilocybin and Escitalopram, vital in Psychiatry and Mental Health Research Topics, appear to rewire the brain differently for Depression recovery. Psilocybin responders showed greater functional connectivity integration across three key networks, reflecting enhanced coordination. Conversely, Escitalopram responders exhibited reduced connectivity within two networks and between two others, suggesting a dampening of self-referential processing. This Neuroscience work, exploring both linear and nonlinear system changes, highlights distinct mechanisms. Understanding these Psychedelics and Drug Studies, including chemical synthesis and alkaloids, is crucial for Medicine and Psychology, offering new insights into treating Depression.
Abstract
Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain network...
An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.
Progress in neuro-psychopharmacology & biological psychiatry – July 25, 2025
Summary
Psychedelic-assisted psychotherapy marks a pivotal evolution in mental health. A review reveals compounds like Psilocybin, LSD, MDMA, and Ketamine are gaining recognition for their unique neurobiological mechanisms. These agents show significant therapeutic potential, effectively addressing complex conditions such as PTSD, depression, and addiction. This integration of psychedelics with psychotherapy offers a promising new direction in treatment.
Abstract
The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by int...
Tags
Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
Frontiers in Neuroergonomics – January 20, 2022
Summary
Psilocybin, a potent hallucinogen, significantly engages brain serotonin 5-HT receptors. Neuroscience, using a radioligand and resting state fMRI in 4 volunteers, measured this alkaloid's receptor occupancy. This agonist achieved an average 39.5% occupancy, with specific default mode network regions, vital for psychology and behavior, showing 63-74%. The inverse agonist radioligand revealed this neurotransmitter receptor influence. Such insights from psychedelics and drug studies are crucial for internal medicine, highlighting psilocybin's impact and its origin as an alkaloid.
Abstract
Psilocybin (a serotonin 2A, or 5-HT 2A , receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The ...
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin
Journal for the Scientific Study of Religion – December 01, 2012
Summary
Remarkably, the mystical experiences occasioned by psilocybin, a powerful hallucinogen, can be precisely measured. A psychology investigation involving 1,602 participants who ingested psilocybin utilized exploratory factor analysis to validate a 30-item Mystical Experience Questionnaire. This psychometrics tool now delineates four dimensions: unity, positive mood, transcendence of time/space, and ineffability. A second sample of 440 confirmed this structure. The findings offer a robust framework for studying spiritual phenomena within psychedelics and drug studies, bridging religion and science.
Abstract
A large body of historical evidence describes the use of hallucinogenic compounds, such as psilocybin mushrooms, for religious purposes. But few sc...
Trial of Psilocybin versus Escitalopram for Depression
New England Journal of Medicine – April 14, 2021
Summary
Psilocybin, a potent hallucinogen, appears to offer antidepressant effects comparable to Escitalopram for individuals navigating depression. A trial comparing these treatments found no significant difference in primary outcomes at six weeks. While secondary measures in Psychology and Psychiatry generally favored Psilocybin, a compound from chemical synthesis and alkaloids influencing neurotransmitter receptors, these require further validation. This emerging area of Medicine and Psychedelics and Drug Studies indicates both options provide initial relief.
Abstract
On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant eff...
The pharmacology of psilocybin
Addiction Biology – October 01, 2002
Summary
Despite its experimental medical use in the 1960s, comprehensive pharmacological data on psilocybin, a major hallucinogen and alkaloid, was surprisingly minimal until recently. This review addresses the significant gap in drug studies, compiling the dispersed information. It details psilocybin's chemical synthesis, its influence on neurotransmitter receptors, and behavioral effects. This synthesis is vital for understanding this psychedelic compound, especially given its growing capacity for abuse and potential in medicine.
Abstract
Abstract Psilocybin (4‐phosphoryloxy‐N,N‐dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide....
Psilocybin Therapeutic Research: The Present and Future Paradigm
ACS Medicinal Chemistry Letters – March 02, 2020
Summary
Psilocybin, the active compound in "magic mushrooms," presents a compelling new avenue in medicine, potentially addressing mental health disorders and addiction without the overdose risks of drugs like cocaine or alcohol. As addiction and suicide deaths rise globally, this psychedelic alkaloid offers urgent therapeutic hope. Future drug studies will leverage diverse academic research themes, including chemical synthesis and potentially data science, to rigorously explore psilocybin's full potential for patient benefit.
Abstract
Psilocybin, an active component in "magic mushroom", may have the potential to meet the therapeutic needs for a number of indications without the a...
Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel–Mediated Cardiotoxicity
The International Journal of Neuropsychopharmacology – December 03, 2021
Summary
Promising hallucinogen psilocybin, used in medicine for psychology, poses less cardiac risk than previously thought. This pharmacology research shows that psilocin, psilocybin's alkaloid metabolite, does not significantly inhibit hERG potassium channels at clinical concentrations. While concerns existed about QT interval prolongation and cardiotoxicity, this adverse effect is not attributable to hERG blockage. This finding is vital for drug studies on psychedelics like MDMA and mescaline, ensuring safe exploration of their neurotransmitter receptor influence on behavior.
Abstract
Abstract Psilocybin, a hallucinogen contained in “magic” mushrooms, holds great promise for the treatment of various psychiatric disorders, and ear...
Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin
Chemistry - A European Journal – February 26, 2020
Summary
Producing 1 gram of psilocybin, a key psychedelic alkaloid, in just 20 minutes is now possible using a mushroom enzyme. This biochemical advance streamlines the chemical synthesis of psilocybin, which is undergoing drug studies for depression. By replacing a complex step in tryptamine chemistry with the enzyme PsiK, 150 mg of the active enzyme was produced for pilot scale. This innovative pharmacology provides a more efficient route to this important compound, improving access and reducing costs for future treatments.
Abstract
Abstract Psilocybin, the principal indole alkaloid of Psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatmen...
Enzymatic Route toward 6‐Methylated Baeocystin and Psilocybin
ChemBioChem – May 31, 2019
Summary
Revolutionary biochemistry now allows for the precise chemical synthesis of modified psilocybin, a key indole alkaloid. This advance in drug studies utilizes three specific enzymes—PsiD, PsiK, and PsiM—to create 6-methylated psilocybin and baeocystin, compounds with significant pharmaceutical interest as psychedelics for depression and anxiety. The process involves crucial methylation. An in silico model of the PsiM enzyme further clarifies its stereochemistry, revealing how its unique chemistry influences substrate preferences, advancing our understanding of alkaloids: synthesis and pharmacology.
Abstract
Abstract Psilocybin and its direct precursor baeocystin are indole alkaloids of psychotropic Psilocybe mushrooms. The pharmaceutical interest in ps...
The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov
Drug Design Development and Therapy – April 01, 2024
Summary
Hundreds of psilocybin clinical trials over two decades are paradoxically hindering its medical approval. Current psychedelic drug studies often lack rigorous pharmaceutical development, proper blinding, and statistical design for participant numbers, leading to inefficiency and excessive costs. Advancing this medicine requires a shift from unfocused chemical synthesis and alkaloid investigations to sequential, well-funded pharmacology. This approach will provide clear direction, accelerating psilocybin's therapeutic potential rather than stalling it.
Abstract
The hundreds of psilocybin clinical trials initiated over the past twenty years comprising a myriad of potential indications may actually be slowin...
The Content of Psilocybin in Norwegian Psilocybe semilanceata
Planta Medica – July 01, 1981
Summary
Certain Norwegian mushrooms, *Psilocybe semilanceata*, contain potent hallucinogenic psilocybin, with dried samples showing concentrations from 0.17 to 1.96%. This significant variability in psilocybin, a key indole alkaloid, reveals the intricate chemistry within these fungi. Smaller mushrooms surprisingly held the highest percentage of this hallucinogen. This insight into plant and fungal interactions is crucial for Psychedelics and Drug Studies, informing chemical synthesis and alkaloids research. It moves beyond historical traditional medicine use, advancing our understanding of these compounds.
Abstract
Psilocybe semilanceata contains hallucinogenic indole alkaloids and has been used as a narcotic drug in Norway. The content of psilocybin, the majo...
The Quantitation of Psilocybin in Hallucinogenic Mushrooms Using High Performance Liquid Chromatography
Journal of Forensic Sciences – October 01, 1983
Summary
Quantifying the psychedelic hallucinogen psilocybin in dried mushrooms is now faster and more accurate. A new chemistry method, utilizing high-performance liquid chromatography (HPLC) with a phosphoric acid mobile phase, precisely measures this alkaloid. The extraction (chemistry) process is simple, taking under 60 minutes for quantitative results. This advancement in drug studies, particularly for psychedelics, streamlines analysis, which is crucial for understanding psilocybin's potential. This chromatography technique offers a robust tool for future chemical synthesis and alkaloid research, potentially impacting areas like phenothiazines and benzothiazines synthesis and activities.
Abstract
Abstract A method using high performance liquid chromatography (HPLC) with an acetonitrile, water, and phosphoric acid mobile phase and a bonded cy...
High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin
Molecular Psychiatry – January 17, 2024
Summary
A compelling Neuroscience finding reveals the hallucinogen Psilocybin acts as an anxiolytic. In larval zebrafish, a model for Psychedelics and Drug Studies, it facilitated exploration and prevented stress responses. This research, crucial for Psychology, shows psilocybin inhibits serotonin neurons in the dorsal raphe nucleus. Understanding this serotonergic neurotransmitter receptor influence on behavior, like insights from Nicotinic Acetylcholine Receptors Study, is vital for drug development to potentially avoid issues like desensitization.
Abstract
Abstract Serotonergic psychedelics are emerging therapeutics for psychiatric disorders, yet their underlying mechanisms of action in the brain rema...
Indigenous psilocybin mushroom practices: An annotated bibliography
Journal of Psychedelic Studies – February 19, 2024
Summary
An essential annotated bibliography compiles 49 texts on Indigenous psilocybin mushroom practices, offering crucial contextualization. This social science resource spans Anthropology, History, and Context (archaeology), exploring diverse uses across Latin American history and culture. It provides an accessible overview of historical and contemporary Indigenous engagement with psychedelics, moving beyond simplistic narratives. The collection, drawing from Library science and Psychedelics and Drug Studies, critically appraises research, including aspects of chemical synthesis and alkaloids, fostering a more nuanced understanding of Indigenous contributions to the global conversation around psilocybin.
Abstract
Abstract This annotated bibliography comprises 49 texts concerning psilocybin mushroom practices developed by Indigenous peoples. The books and art...
Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis
FEBS Letters – October 24, 2024
Summary
Psilocybin, a natural hallucinogen, shows immense promise in Psychedelics and Drug Studies for mental health. Its biosynthesis involves a crucial Kinase enzyme, PsiK, catalyzing phosphorylation. Through detailed Biochemistry, including crystallographic analysis and mutagenesis, its substrate recognition chemistry is now precisely understood. This fundamental chemical insight supports future chemical synthesis and alkaloids research, enabling bioengineering of enhanced psilocybin variants. Such enzyme studies broadly inform drug development, from psychedelics to compounds like Phenothiazines and Benzothiazines Synthesis and Activities.
Abstract
Psilocybin, the natural hallucinogen from Psilocybe (magic) mushrooms, is a highly promising drug candidate for the treatment of depression and sev...
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
International Medical Case Reports Journal – March 01, 2023
Summary
A patient suffering severe, treatment-resistant neuropsychiatric Lyme disease found significant relief using microdosed psilocybin. This potent hallucinogen, increasingly explored in Medicine, particularly within Psychiatry and Psychedelics and Drug Studies, offers a novel approach when conventional drugs fail. For this single individual with Lyme disease, an autoimmune disease, symptoms remitted. Psilocybin's serotonergic and anti-inflammatory properties, relevant to Tryptophan and brain disorders, suggest its potential as a Complementary and Alternative Medicine for mental illness linked to inflammation.
Abstract
Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease i...
Psilocybin rescues sociability deficits in an animal model of autism
OpenAlex – September 10, 2020
Summary
A compelling finding in Psychology and Neuroscience reveals the hallucinogen psilocybin's potential to normalize social deficits in Autism spectrum disorder. In an animal model of Autism, specifically mice exposed to Valproic Acid prenatally, this serotonergic compound significantly rescued social behavioral abnormalities. This work, part of broader Psychedelics and Drug Studies, including areas like Cannabis and Cannabinoid Research, highlights how psilocybin, despite an attenuated acute response in the model, influences neurotransmitter receptors to improve behavior. Such insights offer new directions for Medicine and Psychiatry regarding Autism.
Abstract
Abstract Autism spectrum disorder (ASD) is characterized by core deficits in social interaction. The classic serotonergic psychedelic psilocybin ha...
Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
Therapeutic Advances in Psychopharmacology – September 01, 2025
Summary
Psychedelics and Drug Studies indicate psilocybin therapy significantly decreased suicidal ideation. A review of nine trials, involving 593 psychiatric patients (335 receiving psilocybin), found participants experienced a small but meaningful reduction in suicidal thoughts (SMD = -0.24) compared to control groups. This highlights promising Psychotherapy Techniques and Applications for mental health. Such insights into psychological well-being are vital, considering broader mental health challenges, including those explored in Body Image and Dysmorphia Studies. No studies, however, tracked suicide attempts or deaths.
Abstract
Background: Suicidal ideation, attempts, and deaths present a major and tragic public health concern. Recent trials of psilocybin therapy (PT) have...
Using psilocybin to investigate the relationship between attention, working memory and the serotonin 5-HT1A and 5-HT2A receptors
Journal of Vision – March 17, 2010
Summary
A compelling finding in psychology and neuroscience reveals that the hallucinogen psilocybin, a chemical synthesis and alkaloid, significantly impairs attention. In a drug study with eight healthy volunteers, this psychedelic, acting as a serotonin 5-HT receptor agonist, reduced attentional tracking but left spatial working memory unaffected. Pre-treatment with ketanserin, a 5-HT2A antagonist, did not reverse psilocybin's effect on attentional performance, suggesting a primary role for the 5-HT1A receptor in the prefrontal cortex. This neurotransmitter receptor influence on behavior highlights a dissociation in cognitive psychology, possibly reflecting a reduced ability to ignore distractions.
Abstract
Increasing evidence suggests a link between attention, working memory, serotonin (5-HT) and prefrontal cortex activity. In an attempt to tease out ...
Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma
Journal of Chromatography B – December 07, 2020
Summary
Understanding how psilocybin, a psychedelic, acts in the body is crucial for drug studies. A robust bioanalysis method now accurately measures psilocin, its active metabolite, and 4-hydroxyindole-3-acetic acid in plasma. This chemistry uses protein precipitation for sample preparation, followed by chromatography and tandem mass spectrometry with electrospray ionization. The method boasts 100-109% accuracy and ≥94.7% recovery, covering concentrations from a 25 mg psilocybin dose. This advances pharmacokinetics, crucial for understanding neurotransmitter receptor influence on behavior and forensic toxicology.
Abstract
Psilocin is the active metabolite of psilocybin, a serotonergic psychedelic substance. It is used recreationally and investigated in substance-assi...
Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa
South African Journal on Human Rights – January 02, 2023
Summary
South Africa’s criminalization of psilocybin mushrooms is unjustifiable. An interpretation of Section 12(2) of the Constitution establishes cognitive liberty as a fundamental human right, protecting both mind and body. Current legislation, including the Drugs and Drug Trafficking Act, directly conflicts with this constitutional protection. A political science analysis concludes that criminalizing psilocybin, a psychedelic, lacks justifiable grounds. This challenges existing drug law and calls for a re-evaluation of human rights regarding consciousness.
Abstract
The principle of cognitive liberty is assessed as a ground for challenging the constitutionality of the criminalisation of psilocybin mushrooms. To...
Psilocybin as a healer
Consciousness Spirituality & Transpersonal Psychology – September 12, 2022
Summary
Psilocybin microdosing, involving a hallucinogen, appears to significantly boost mental health and creativity. Twelve individuals shared their lived experience, detailing how it subtly shifts perception and feeling. Most reported improved wellbeing, productivity, and a deeper connection. This qualitative insight contributes valuable data to Psychology, encompassing clinical, social, and psychedelic drug studies, informing psychotherapists. While chemical synthesis of alkaloids is crucial, this highlights psilocybin's profound psychological impact.
Abstract
This phenomenological research explored the fast-growing societal trend in psilocybin microdosing, whereby a sub-perceptual amount of the psychedel...
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial
Journal of Psychopharmacology – August 29, 2025
Summary
A compelling clinical trial suggests psilocybin, a potent hallucinogen, significantly reduces traumatic stress. In an open-label investigation with 22 participants, average PTSD scores dropped by nearly 30 points by week 4. The drug demonstrated good tolerability; 91.4% of administration-day adverse events resolved quickly, with no serious events. This points to psilocybin's potential in medicine and psychiatry, particularly for psychotherapy applications. Such psychedelics and drug studies offer a complementary approach to traditional treatments, avoiding the need for anesthesia.
Abstract
Background: Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being s...
Psilocybin reduces functional connectivity and the encoding of spatial information by neurons in mouse retrosplenial cortex
OpenAlex – April 22, 2024
Summary
The hallucinogen Psilocybin profoundly disrupts spatial perception, a key Neuroscience finding. In 25 mice, the retrosplenial cortex, a brain region vital for navigation, showed significant alterations. Psilocybin reduced neuronal place specificity by 40% and functional connectivity among neurons by 30%. This biochemical analysis suggests the psychedelic increases neural signaling entropy. This effect on the cortex, crucial for Psychology and Perception, was largely blocked by targeting specific neurotransmitter receptors, providing insight into disorientation reported in Psychedelics and Drug Studies.
Abstract
Psychedelic drugs have profound effects on perception, cognition, and mood. How psychedelics affect neural signaling to produce these effects remai...
Magic mushrooms and mood: exploring Psilocybin as a depression treatment
Journal of the Pakistan Medical Association – December 20, 2025
Summary
A significant development in Psychiatry: Psilocybin, a potent hallucinogen, is emerging as a viable treatment for Major Depressive Disorder. This psychedelic compound acts on serotonergic receptors, inducing altered perception and psychological effects. Recognized by the FDA with "breakthrough" therapy status, Psilocybin offers a novel approach in Medicine. Studies highlight its effectiveness in alleviating depressive symptoms, often integrated with psychological therapy. Its potential to transform mental health treatment is driving intense interest in Psychedelics and Drug Studies.
Abstract
Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psyche...
Psilocybin: a psychedelic alternative to antidepressants?
Pharmaceutical journal/The pharmaceutical journal – January 01, 2022
Summary
A single 25mg dose of the hallucinogen psilocybin, combined with psychological support, dramatically improved symptoms for individuals with treatment-resistant depression for up to 12 weeks. This significant finding, from the largest trial to date (November 2022), highlights psilocybin's potential in Psychiatry. Precision in Chemical synthesis and alkaloids allows for its use as Medicine. This area of Psychedelics and Drug Studies shows promise, offering new avenues in Pharmacology and Psychology for severe mental health conditions.
Abstract
In November 2022, the largest trial to date of the psychedelic drug, psilocybin, showed that — alongside psychological support — a single 25mg dose...
Psilocybin for Depression and Anxiety in Cancer Patients
OpenAlex – January 01, 2025
Summary
In a significant finding for medicine, psilocybin, combined with psychotherapist support, dramatically reduced anxiety and depression in 51 cancer patients. This work in clinical psychology and psychiatry revealed large symptom decreases, improved quality of life, and optimism. Crucially, around 80% of participants maintained these benefits six months later. Such results advance diverse academic research themes in psychology and psychedelics and drug studies, showcasing the therapeutic potential of compounds like psilocybin, a naturally occurring alkaloid.
Abstract
Abstract Fifty-one cancer patients with symptoms of depression and anxiety were enrolled in a randomized, double-blind, crossover trial using low-d...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment
International Journal of Drug Policy – August 01, 2025
Summary
Public support for psilocybin policies significantly increases when its benefits and safety are clearly communicated. A recent survey of 1,500 adults revealed that providing balanced information about this potent hallucinogen and alkaloid boosted policy support by 18%. Furthermore, 65% of participants reported strengthened positive beliefs about psilocybin's potential. This finding, crucial for psychology and drug studies, suggests informed discourse can reshape public perception, impacting future business and therapeutic applications of psychedelics.
Abstract
Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further...
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
OpenAlex – December 09, 2025
Summary
Psilocybin offers a compelling new direction for treating alcohol use disorder, a condition where existing therapies often struggle to prevent relapse. Recent clinical trials indicate psilocybin significantly reduces alcohol craving. However, its broader impact on overall alcohol consumption requires further clarification. Subsequent evaluations will benefit from larger participant cohorts and standardized assessment tools to fully understand its therapeutic potential.
Abstract
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to p...
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review
Preprints.org – October 17, 2025
Summary
Psilocybin, a psychedelic alkaloid, shows promise in reducing alcohol cravings, a key behavior in alcohol use disorder. Current drug studies indicate psilocybin's potential to address this condition, which severely impacts overall well-being and sexuality. While chemical synthesis ensures consistent compound availability, its effect on overall alcohol consumption remains less clear. Future trials, utilizing advanced technology for standardized assessments and larger participant groups, are needed to fully clarify this therapeutic approach.
Abstract
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to p...
Fallbeispiele zur Therapie der rezidivierenden Depression mit Psilocybin
Nervenheilkunde – April 01, 2024
Summary
Psilocybin, a synthesized alkaloid, shows immense potential in treating recurrent depression, offering new avenues in Psychology and Medicine. Two detailed patient case studies highlight its positive impact on individuals' lives. While interest in Psychedelics and Drug Studies is growing globally, these examples also reveal that not all patients experience long-term benefits. This nuanced perspective is crucial for understanding Psilocybin's broader therapeutic role, potentially informing Body Image and Dysmorphia Studies.
Abstract
ZUSAMMENFASSUNG Der Artikel stellt 2 Behandlungsverläufe von Patienten mit rezidivierender Depression gegenüber, welche mit Psilocybin behandelt wu...
The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping Review
Preprints.org – June 19, 2025
Summary
Early findings suggest psilocybin, paired with psychotherapy, significantly reduces heavy drinking days for individuals with alcohol use disorder. A review of 12 studies, including 7 RCTs, from a pool of 757 records, highlights its promise in psychiatry and medicine. These studies, often involving clinical psychology and psychotherapists, show psilocybin’s potential for relapse prevention across diverse populations. While promising, current data has small sample sizes and short follow-up periods, necessitating further rigorous investigation into this psychedelic compound's efficacy and safety for broader use.
Abstract
Background: Alcohol Use Disorder (AUD) is a chronic pathological condition with significant burdens throughout the world. Despite the effectiveness...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...